New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
GNOM ETF · Global X Genomics & Biotechnology ETF - USD
The GNOM Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: Solactive Genomics Index. The GNOM ETF provides physical exposure, so by buying it you actually own parts of all the 48 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 3/13/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.-1.33%
Last price
$43.24
1M perf.
-5.57%
1M flows
N/A
AuM
€41M
E/R
0.5%
Rating
ESG Consensus®
GNOM
$43.24
Performance & flows
Segment for quartile rank
December 15, 2025 → March 13, 2026
Create a free account to view the flows graph
GNOM
$43.46
-6.28%
BioTech & Genomics
-5.41%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -5.57%  | -6.28% | +25.75%  | -9.66%  | -54.21% | -9.42% | -4.83% | -4.83% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/13/2026
$43.34
1D NAV change
-0.67%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
48
Inception date
4/5/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The Global X Genomics & Biotechnology ETF seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
GNOG
1M perf.
-5.61%
E/R
0.5%
HTEC
1M perf.
-4.76%
E/R
0.8%
DOCG
1M perf.
-7.52%
E/R
0.49%
WDNA
1M perf.
-1.01%
E/R
0.45%
BTEC
1M perf.
-3.36%
E/R
0.35%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -6.28% | +25.75% | -9.66% | -54.21% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
87.04%
Switzerland
3.05%
United Kingdom
1.99%
Cayman Islands
1.55%
Singapore
1.38%
Netherlands
1.08%
Unavailable
3.90%
Sectors
Health Care
87.95%
Unavailable
12.05%
Diversification
Total weight of top 15 holdings out of 48
Top 15 holdings
Data as of January 31, 2026
MODERNA INC
ARROWHEAD PHARMACEUTICALS INC
US74006W2070
ILLUMINA
GUARDANT HEALTH INC
NATERA
VERTEX PHARMACEUTICALS
BIONTECH SE ADR
Create a free account to view top holdings
BIOMARIN PHARMACEUTICAL
AVIDITY BIOSCIENCES
BIO-TECHNE CORP
CRISPR THERAPEUTICS
ALNYLAM PHARMACEUTICALS
VERACYTE INC/D
BRISTOL-MYERS SQUIBB
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
ESG Consensus® by Conser
Data as of December 31, 2025
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about GNOM ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
GNOM’s has a Final Sustainability Grade of either A+, A, or A-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
95.59% of holdings have positive scoring
8.48% of holdings have negative scoring
20.70%
51.19%
23.70%
Consensus levels
Strong
Medium
Weak
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
Solactive Genomics Index - USD
Index ticker
SOLGNOM Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Global X
Global X ID Card
Number of funds
482
Total AuM
€135.05B
Expense ratio range
0.02% - 2.06%
Average expense ratio
0.5815%
Top 5 funds by Global X
| AuM | ||
|---|---|---|
PAVE | Global X U.S. Infrastructure Development ETF | €9.95B |
SHLD | Global X Defense Tech ETF | €7.12B |
QYLD | Global X Nasdaq 100 Covered Call ETF | €7.09B |
AIQ | Global X Artificial Intelligence & Technology ETF | €6.55B |
COPX | Global X Copper Miners ETF | €6.06B |
Frequently asked questions about GNOM
What does Global X Genomics & Biotechnology ETF - USD, GNOM, invest in?
GNOM is a Passive ETF. This ETF provides exposure to Equities.
Which benchmark or index does GNOM replicate?
GNOM tracks the Solactive Genomics Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of GNOM?
GNOM carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
When was GNOM launched?
GNOM was introduced to the market on April 5, 2019. It trades on United States
Who is the ETF issuer of GNOM?
Global X Genomics & Biotechnology ETF - USD, GNOM, is provided by Global X. Learn more about Global X here.
What is the current assets under management (AUM) of GNOM?
GNOM oversees €41M in assets as of March 13, 2026.
How has GNOM performed lately?
Based on data from March 13, 2026, GNOM returned -5.57% over the past month, -6.28% over the last three months and -4.83% year-to-date.
What are the latest inflows or outflows for GNOM?
As of March 13, 2026, GNOM recorded net flows of -€1.6M year-to-date.
Does GNOM distribute dividends?
GNOM follows a distributing dividend policy, meaning it pays out income to investors. As of March 13, 2026, its 12-month trailing yield was 1.44%.
What are the main country or region exposures of GNOM?
As of January 31, 2026, GNOM has significant geographic allocations in USA, Switzerland and United Kingdom.
In which sector or theme does GNOM invest in?
As of January 31, 2026, GNOM focuses largely on Health Care.
How many securities does GNOM hold and how diversified is it?
As of January 31, 2026, GNOM holds 48 positions in its portfolio, with 63.95% of assets concentrated in its top 15 holdings.
What are the main positions in GNOM?
As of January 31, 2026, GNOM top three holdings include MODERNA INC, ARROWHEAD PHARMACEUTICALS INC and US74006W2070.
What is the base currency of GNOM?
The base currency of GNOM is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
